医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Jubilant Biosys and Orion Corporation Announce Unique Collaborative Discovery Program in Pain Management Area

2014年05月14日 AM05:30
このエントリーをはてなブックマークに追加


 

NOIDA, India

Jubilant Biosys, a Bengaluru-based subsidiary of Jubilant Life Sciences, and Orion Corporation (Orion), the largest pharmaceutical company in Finland, today announced a path-breaking drug discovery collaboration to discover small molecule inhibitors in the neuroscience therapeutic area. The research deal is aimed at developing drug that can benefit the large population of people with unmet needs in the pain management area.

As per the terms of agreement, Jubilant’s extensive experience in drug discovery and pre-clinical development will be utilised by Orion to address pain management needs of Central Nervous System (CNS). Jubilant will offer integrated drug discovery services across early discovery, synthetic and medicinal chemistry including scale up and pre-clinical services. The research for the project, which has been initiated, will be undertaken primarily at state-of-the-art R&D labs of Jubilant Biosys (India) and some parts at Jubilant Discovery Center, USA.

Dr. Subir Kumar Basak, President of Jubilant Biosys Ltd., said: “We are excited to partner with Orion to offer integrated drug discovery services. Over the past few years, we have been strengthening our therapeutic area focused discovery platform, and this partnership serves as a validation of our efforts. We are confident of offering successful results to Orion at various stages of research.”

Dr. Jukka Sallinen, Head of CNS Research of Orion Pharma R&D, said: “Jubilant Biosys is widely recognised for its expertise in offering integrated services in Drug Discovery and Development Solutions and for its prodigious capabilities in Pain and Inflammation. With established ability to develop successful drugs, we consider Jubilant as our ideal partner to take forward our strategic business plans with optimum time-to-market and accuracy.”

Jubilant will receive research funding from Orion for delivering Hit, Lead Generation and Optimization milestone, according to a pre-defined research plan. Under the royalty based alliance, Orion will provide royalty to Jubilant and will retain ownership of the compounds developed under the collaboration with exclusive worldwide rights.

About Jubilant Biosys

Jubilant Biosys is a Bengaluru based subsidiary of Jubilant Life Sciences Ltd. which is headquartered in Noida, India. Jubilant Biosys provides integrated drug discovery solutions to the global pharmaceutical industry. Biosys has pioneered the risk shared collaborative discovery research model and demonstrated their capabilities over the years through multiple partnerships with global pharmaceuticals firms in the therapeutic areas of Oncology, Metabolic Disorders, Pain & Inflammation, CNS and others. Visit us: www.jubilantbiosys.com; www.jubl.com.

About Orion

Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. Visit http://www.orion.fi.

CONTACT

Perfect Relations
Sudipta Das
+91 9650602489
sdas@perfectrelations.com
or
Jubilant
Life Sciences
Nidhi Malik
nidhi_malik@jubl.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Brightree发布面向居家医疗器械的首个患者App
  • Brightreeが初のHME向け患者アプリを発表
  • Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
  • ポットネットワーク・ホールディングスがSEC報告会社登録に基づきPCAOB監査人による完全な監査・レビュー済みの財務報告書を公表
  • Takeda Receives Clearance from the Japan Fair Trade Commission for the Proposed Acquisition of Shire plc